Summary Brief Abstract Citation MEDLINE ASN.1 XML/SGML LinkOut Related Articles Protein Links Nucleotide Links Popset Links Structure Links Genome Links OMIM Links

1: Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997 Nov-Dec;25(6):391-5

Related Articles, Books

[Fluoxetine in the treatment of borderline personality disorder].

[Article in Spanish]

Silva H, Jerez S, Paredes A, Salvo J, Renteria P, Ramirez A, Montes C.

Departamento de Psiquiatria y Salud Mental, Facultad de Medicina, Universidad de Chile.

OBJECTIVE: This study evaluates the therapeutic effect of fluoxetine, a selective serotonin reuptake inhibitor, in borderline personality disorder. METHOD: 46 patients with borderline personality disorder according to DSM-III-R and Diagnostic Interview for Borderlines (DIB-R) criteria, were given fluoxetine 20-60 mg for seven weeks. They were evaluated each week using Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning Scale (GAF), Hamilton Depression Rating Scale (HDRS) and a clinical Impulsivity Scale. RESULTS: There were significant improvements in BPRS, HDRS, GAF and Impulsivity Scale from the first week of the treatment. These improvements continued until the seven week of treatment. The favourable outcome was not only due to the improvement in depression and impulsivity scores, but also to the decline of global psychopathology. CONCLUSIONS: The data suggest that fluoxetine is an effective pharmacologic treatment for borderline personality disorder. These findings support the hypothesis of a 5-HT dysfunction in borderline personality disorder.

Publication Types:

• Clinical trial

PMID: 9477607 [PubMed - indexed for MEDLINE]